Your session is about to expire
← Back to Search
Monoclonal Antibodies
PF-07257876 for Ovarian Cancer
Phase 1
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through up to 2 years
Awards & highlights
Summary
This trial tests a new medicine called PF-07257876 that targets two proteins on cancer cells. It is for patients with advanced or metastatic tumors who have no other treatment options. The medicine helps the immune system recognize and attack the cancer cells.
Eligible Conditions
- Squamous Cell Carcinoma
- Ovarian Cancer
- Non-Small Cell Lung Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline through up to 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through up to 2 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of participants with adverse events (AEs)
Number of participants with clinically significant laboratory abnormalities
Number of participants with dose limiting toxicities (DLTs) in Dose Escalation (Part 1)
+1 moreSecondary study objectives
Duration of response (DOR)
Immunogenicity of PF-07257876
Intratumor PD-L1 expression
+12 moreTrial Design
3Treatment groups
Experimental Treatment
Group I: Dose Expansion (Part 2) - Cohort 2 (SCCHN)Experimental Treatment1 Intervention
Participants with squamous cell carcinoma of the head and neck (SCCHN) will receive PF-07257876 at the recommended dose from Part 1.
Group II: Dose Expansion (Part 2) - Cohort 1 (NSCLC)Experimental Treatment1 Intervention
Participants with non-small cell lung cancer (NSCLC) will receive PF-07257876 at the recommended dose from Part 1.
Group III: Dose Escalation (Part 1)Experimental Treatment1 Intervention
Participants will receive PF-07257876 at escalating dose levels.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PF-07257876
2021
Completed Phase 1
~30
Find a Location
Who is running the clinical trial?
PfizerLead Sponsor
4,625 Previous Clinical Trials
14,284,165 Total Patients Enrolled
20 Trials studying Ovarian Cancer
2,596 Patients Enrolled for Ovarian Cancer
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,518 Previous Clinical Trials
11,458,741 Total Patients Enrolled
12 Trials studying Ovarian Cancer
2,062 Patients Enrolled for Ovarian Cancer
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:Research Study Groups:
This trial has the following groups:- Group 1: Dose Escalation (Part 1)
- Group 2: Dose Expansion (Part 2) - Cohort 2 (SCCHN)
- Group 3: Dose Expansion (Part 2) - Cohort 1 (NSCLC)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger